M&A Deal Summary

Bausch Health Acquires Sprout Pharmaceuticals

On August 20, 2015, Bausch Health acquired life science company Sprout Pharmaceuticals from Auven Therapeutics for 1.0B USD

Acquisition Highlights
  • This is Bausch Health’s 19th transaction in the Life Science sector.
  • This is Bausch Health’s 4th largest (disclosed) transaction.
  • This is Bausch Health’s 19th transaction in the United States.
  • This is Bausch Health’s 2nd transaction in North Carolina.

M&A Deal Summary

Date 2015-08-20
Target Sprout Pharmaceuticals
Sector Life Science
Buyer(s) Bausch Health
Sellers(s) Auven Therapeutics
Deal Type Add-on Acquisition
Deal Value 1.0B USD
Advisor(s) Perella Weinberg Partners (Financial)
Sullivan & Cromwell (Legal)

Target

Sprout Pharmaceuticals

Raleigh, North Carolina, United States
website
Sprout Pharmaceuticals, Inc. is a life science company focused on women's sexual health. Sprout is passionate about women's sexual health and has focused solely on the delivery of a treatment option for the unmet need of premenopausal women with acquired, generalized Hypoactive Sexual Desire Disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance.

Search 192,510 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Bausch Health

Laval, Quebec, Canada

website


Category Company
Sector Life Science
Employees19,900
Revenue 8.1B USD (2022)
DESCRIPTION

Bausch Health is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology, and branded generics. Bausch Health is based in Laval, Quebec.


DEAL STATS #
Overall 32 of 35
Sector (Life Science) 19 of 21
Type (Add-on Acquisition) 24 of 25
State (North Carolina) 2 of 2
Country (United States) 19 of 22
Year (2015) 5 of 6
Size (of disclosed) 4 of 27
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-07-17 Amoun Pharmaceutical Company

Cairo, Egypt

Amoun Pharmaceutical Company is a developer, manufacturer, marketer, distributer, and export of a wide range of human pharmaceutical and animal health products. Amoun Pharmaceutical Company is based in Cairo, Egypt.

Buy $800M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-10-15 Synergetics USA

O’Fallon, Montana, United States

Synergetics USA, Inc. is a provider fo precision surgical devices.

Buy -

Seller(S) 1

DESCRIPTION

Auven Therapeutics is a private equity firm focused on investing in life science companies. Auven looks to acquire controlling ownership in promising therapeutic products or platforms and develop programs to selling them as clinically and commercially validated products to established pharmaceutical companies. Auven Therapeutics was established in 2007 and is headquartered in St. Thomas, US Virgin Islands.


DEAL STATS #
Overall 2 of 4
Sector (Life Science) 2 of 3
Type (Add-on Acquisition) 2 of 3
State (North Carolina) 1 of 1
Country (United States) 1 of 1
Year (2015) 1 of 1
Size (of disclosed) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-10-15 Spirogen

London, United Kingdom

The Spirogen group was founded in 2001 as a spin-out from several institutions including University College London and with partial funding by Cancer Research UK. It is majority owned by Auven Therapeutics. It has developed a novel class of highly potent cytotoxic warheads based on its proprietary pyrrolobenzodiazepines (PBDs), DNA minor groove binding agents, which bind and cross-link specific sites of DNA of the cancer cell.

Sell $240M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-10-26 Ocular Technologies Sarl

Lyme Park, South Africa

Ocular Technologies Sarl is a specialist enterprise communications company and turnkey services provider. The company has made its mark at the forefront of the industry as a preferred partner for large-scale corporates, SMMEs and government affiliates alike.

Sell $40M